2 unknown, 2 withdrawn, 1 completed, 1 recruiting. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Unknown 2, Withdrawn 2, Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Prophylaxis: new trials by email Literature Review of Prophylaxis trials Research Report on Prophylaxis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction Apixaban 2.5 MG PO BID, Control (Standard treatment) - Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus | Phase 3 | Recruiting | National Institute of Cardiovascular Diseases, Pakistan | 472 | 2024-12-02 | 2024-12-19 |
| Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) Islatravir, Placebo to FTC/TDF, FTC/TDF - HIV-I, Human Immunodeficiency Virus Type 1 | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 730 | 2021-02-24 | 2026-02-04 |
| Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals Hydroxychloroquine (HCQ), Placebo oral tablet - COVID19, Sars-CoV2 | Phase 3 | Withdrawn | Abderrahmane Mami Hospital | 2020-04-28 | 2020-08-28 | |
| Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) Hydroxychloroquine, Placebo - COVID-19, Corona Virus Infection | Phase 3 | Unknown | Louisiana State University Health Sciences Center in New Orleans | 1700 | 2020-04-27 | 2020-09-02 |
| HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial Hydroxychloroquine Pre-Exposure Prophylaxis, Placebo oral tablet - Prophylaxis, COVID-19 | Phase 3 | Unknown | GeoSentinel Foundation | 374 | 2020-04-24 | 2020-04-22 |
| HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers Hydroxychloroquine, Placebo - Sars-CoV2, Infection Viral | Phase 3 | Withdrawn | Medical University of Vienna | 2020-04-01 | 2022-04-12 | |
| A Long Term Safety Study of BCX7353 in Hereditary Angioedema BCX7353 - Hereditary Angioedema, HAE | Phase 2 / Phase 3 | Completed | BioCryst Pharmaceuticals | 387 | 2018-02-16 | 2023-06-18 |
COVID-19 (3) · Acquired Immunodeficiency Syndrome (1) · Angioedemas, Hereditary (1) · Anterior Wall Myocardial Infarction (1) · Coronavirus Infections (1) · Ventricular Dysfunction, Left (1) · Virus Diseases (1)
Infections (5) · RNA Virus Infections (4) · Virus Diseases (4) · Coronaviridae Infections (3) · Lung Diseases (3) · Nidovirales Infections (3) · Pneumonia (3) · Pneumonia, Viral (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Cardiovascular Diseases (2) · Coronavirus Infections (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Vascular Diseases (2)
Hydroxychloroquine (3) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · apixaban (1) · berotralstat (1) · islatravir (1)
Abderrahmane Mami Hospital (1) · BioCryst Pharmaceuticals (1) · GeoSentinel Foundation (1) · Louisiana State University Health Sciences Center in New Orleans (1) · Medical University of Vienna (1) · Merck Sharp & Dohme LLC (1) · National Institute of Cardiovascular Diseases, Pakistan (1)
United States (4) · South Africa (2) · Australia (1) · Austria (1) · Denmark (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Israel (1) · Italy (1) · New Zealand (1) · North Macedonia (1) · Pakistan (1) · Poland (1)
Bradley A Connor, MD (1) · Henriette Farkas, MD (1) · Jalila Ben Khelil, Pr (1)
PMID 34161665, PMID 35820771, PMID 36408587, PMID 38006972, PMID 38020288, PMID 40490218